Leaflet VEKLURY 100mg powder for concentrate for solution for infusion

Indicated for: COVID-19

Route of administration: infusion

Substance: remdesivir (antiviral)

ATC: J05AB16 (Antiinfectives for systemic use | Direct acting antivirals | Nucleosides and nucleotides excl. reverse transcriptase inhibitors)

Precautions:
Dose adjustment in renal impairment
Dose adjustment in renal impairment

Dose adjustment may be needed in kidney disease.

Major drug interactions
Major drug interactions

This medicine may have important interactions with other medicines.

Breastfeeding warning
Breastfeeding warning

Use during breastfeeding only on medical advice.

Pregnancy warning
Pregnancy warning

Use during pregnancy only on medical advice.

Remdesivir is an antiviral medication used for the treatment of SARS-CoV-2 infection, which causes COVID-19. It is a nucleotide analog that inhibits viral RNA polymerase, blocking the replication of the virus in infected cells. Remdesivir has been approved for use in moderate to severe cases of COVID-19, particularly in hospitalized patients requiring supplemental oxygen.

The medication is administered intravenously, usually once daily, for a duration of 5 to 10 days, depending on the severity of the disease. It is most effective when given in the early stages of infection, before the disease progresses to critical forms.

Common side effects include nausea, headache, elevated liver enzymes (transaminases), and injection site reactions. Rarely, severe allergic reactions or kidney dysfunction may occur. Regular monitoring of liver and kidney function is essential during treatment.

Remdesivir is used under strict medical supervision and is reserved for hospitals and medical facilities. While it can reduce hospitalization duration and disease progression, its effectiveness varies depending on the stage of the disease and the patient’s overall condition.

General data about VEKLURY 100mg

  • Substance: remdesivir
  • Date of latest medicines list: 01-10-2025
  • Product code: W70543001
  • Concentration: 100mg
  • Pharmaceutical form: powder for concentrate for solution for infusion
  • Quantity: 1
  • Product type: Generic medicine
  • Prescription status: P-RF - Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.

Marketing authorisation

  • Manufacturer: GILEAD SCIENCES IRELAND UC - IRLANDA
  • Holder: GILEAD SCIENCES (GSR) S.R.L. - ROMANIA
  • Number: 962/2024/02
  • Shelf life: 4 years-flac. nesigilate

Concentrations available for remdesivir

  • 100mg
  • 5mg/ml